Delivery via inhaler could dramatically expand Epinephrine’s clinical utility for emergency self-administration to prevent worsening of early symptoms of anaphylaxis Roden, The Netherlands — August 4th, 2020 — PIMS-E, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for allergic reactions and anaphylaxis, announced the completion of the dosing of 10 subjects in […]